ATE77945T1 - Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme. - Google Patents

Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.

Info

Publication number
ATE77945T1
ATE77945T1 AT88303144T AT88303144T ATE77945T1 AT E77945 T1 ATE77945 T1 AT E77945T1 AT 88303144 T AT88303144 T AT 88303144T AT 88303144 T AT88303144 T AT 88303144T AT E77945 T1 ATE77945 T1 AT E77945T1
Authority
AT
Austria
Prior art keywords
liposomes
cells
nucleosides
phosphorylated
viral dna
Prior art date
Application number
AT88303144T
Other languages
English (en)
Inventor
John N Weinstein
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE77945T1 publication Critical patent/ATE77945T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88303144T 1987-04-10 1988-04-08 Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme. ATE77945T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3717887A 1987-04-10 1987-04-10
US17778888A 1988-04-05 1988-04-05
EP88303144A EP0286418B1 (de) 1987-04-10 1988-04-08 Anti-retrovirale Stoffe und dazugehörige Verabreichungssysteme

Publications (1)

Publication Number Publication Date
ATE77945T1 true ATE77945T1 (de) 1992-07-15

Family

ID=26713879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88303144T ATE77945T1 (de) 1987-04-10 1988-04-08 Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.

Country Status (8)

Country Link
EP (1) EP0286418B1 (de)
JP (1) JPH02501576A (de)
AT (1) ATE77945T1 (de)
AU (1) AU601848B2 (de)
CA (1) CA1315684C (de)
DE (1) DE3872563T2 (de)
IL (1) IL86009A (de)
WO (1) WO1988007854A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JPH03501253A (ja) * 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
FR2640508B1 (fr) * 1988-12-19 1994-07-01 Dietlin Francois Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire
CA2055497A1 (en) * 1989-03-13 1990-09-14 Kenneth N. Matsumura Method for reducing side effects of a drug
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
AU7920491A (en) * 1990-06-21 1992-01-02 Patrick T. Prendergast Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
US5137876A (en) * 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5773027A (en) * 1994-10-03 1998-06-30 Michael G. Bergeron Liposomes encapsulating antiviral drugs
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
DE3687069T2 (de) * 1985-03-16 1993-03-25 Wellcome Found Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
JPS62501777A (ja) * 1985-08-26 1987-07-16 アメリカ合衆国 ２′，３′―ジデオキシシチジンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤

Also Published As

Publication number Publication date
DE3872563T2 (de) 1992-12-03
WO1988007854A1 (en) 1988-10-20
AU1701788A (en) 1988-11-04
JPH02501576A (ja) 1990-05-31
AU601848B2 (en) 1990-09-20
EP0286418A1 (de) 1988-10-12
EP0286418B1 (de) 1992-07-08
IL86009A0 (en) 1988-09-30
CA1315684C (en) 1993-04-06
IL86009A (en) 1991-09-16
DE3872563D1 (de) 1992-08-13

Similar Documents

Publication Publication Date Title
ATE77945T1 (de) Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.
DE68928884D1 (de) Rekombinante Retroviren
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ES2149267T3 (es) Carbonilos ciclicos substituidos y derivados de los mismos utiles como inhibidores de la proteasa retroviral.
EA199901031A1 (ru) Производные бензимидазола
SE8704298D0 (sv) Compounds for use in therapy
ES2081491T3 (es) Nuevo polipeptido y farmaco anti-vih preparado a partir de este polipeptido.
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
TR200102024T2 (tr) Yeni tedavi.
ATE58478T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
Skurkovich et al. Interferon-containing plasma: the preparation for treatment of viral infections
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
DE68929084D1 (de) Arzneimittel zur Verhinderung einer Infektion mit dem für AIDS verantwortlichen Virus
TH3782EX (th) นิวคลีโอไซด์ที่ต่อต้านไวรัส
GT199000061A (es) Derivados amino acidos
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
TH13510EX (th) ระบบนำส่งยาเฉพาะที่ที่ดีขึ้นซึ่งแทรกซึมผ่านผิวหนังได้เพิ่มขึ้น
TH13799EX (th) สารต้าน-เอชบีวี พิริมิดีนนิวคลีโอไซด์
ATE108654T1 (de) Anti-hiv zusammensetzungen.
JPS6471815A (en) Antiviral composition containing 5-amino-2- (4-methylpiperidine-1-yl)phenyl-4- chlorophenylmethanone
TH8797EX (th) องค์ประกอบต่อต้านไวรัสหรือต่อต้านแบคทีเรียและวิธีการใช้
CA2401295A1 (en) Process for preparing an anti viral medicinal product from plant extracts

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee